Pharmaceutical Technology

FEBRUARY 13, 2023

Proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules composed of two ligands joined by a linker, designed to degrade proteins by recruiting an E3 ligase to the target, resulting in its subsequent ubiquitylation and degradation by the proteosome.

Development 147

Development Protein Immune Response Trials 147

XTalks

FEBRUARY 5, 2025

Avtozma is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6) receptor antagonist that works by targeting specific inflammatory proteins to dampen immune responses. Avtozma was submitted for regulatory approval to the FDA in January 2024 and the European Medicines Agency (EMA) in February 2024.

FDA Approval 102

FDA Approval Marketing Antibody Immune Response 102

pharmaphorum

JULY 18, 2022

“It is programmed and coded for the production of the full-length spike protein of the coronavirus. It then elicits an immune response against that spike protein. When you have mucosal immunity, the immunoglobulins called IgAs start neutralising the virus at the point of entry. The inhalant version.

Vaccine 138

Vaccine Vaccination Development Immune Response 138

Pharmaceutical Technology

MAY 29, 2023

A protein-based vaccine, Nuvaxovid has been recommended for MA for use as a primary series in individuals of the age 12 years and above and as a booster in those aged 18 years and older to prevent Covid-19. NVX-CoV2373 is developed by making copies of the surface spike protein of the SARS-CoV-2 virus that causes Covid.

Vaccine 130

Vaccine Vaccination Protein Immune Response 130

BioSpace

NOVEMBER 7, 2022

Researchers from the University of Washington have developed an investigational vaccine that can safely elicit an immune response against the HER2 protein, a key marker in breast cancer.

Immune Response 86

Immune Response Vaccine Vaccination Protein 86

Pharmaceutical Technology

NOVEMBER 20, 2022

Health Canada has granted expanded authorisation for Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted) [Nuvaxovid; NVX-CoV2373] as a homologous booster for usage in adults aged 18 and above. Novavax president and CEO Stanley Erck said: “Canadians now have access to our protein-based Nuvaxovid Covid-19 vaccine as an adult booster.

Vaccine 147

Vaccine Vaccination Immune Response Protein 147

The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. “In Induction of innate immunity was investigated via specific cytokine markers.

Immune Response 52

Immune Response Vaccine Vaccination Antibody 52

pharmaphorum

DECEMBER 4, 2020

Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets. Valneva is paying 30% of development costs and in return Pfizer will pay tiered royalties starting at 19% and will lead late-stage development.

Vaccine 119

Vaccine Vaccination Bacterium Protein 119

BioPharma Reporter

MAY 25, 2021

An experimental recombinant protein nanoparticle vaccine that stimulates a strong immune response is hoping to address that inefficiency. Seasonal flu vaccines typically work 40-60% of the time, according to the US Centers for Disease Control and Prevention (CDC).

Vaccine 91

Vaccine Vaccination Immune Response Production 91

Pharmaceutical Technology

JANUARY 19, 2023

Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain. It has been developed using the company’s recombinant nanoparticle technology. In the Phase II trials, adult participants received a single Nuvaxovid booster dose six months after their initial two-dose vaccine doses.

Vaccine 147

Vaccine Vaccination Immune Response Protein 147

Cloudbyz

MARCH 5, 2024

In the intricate dance of drug discovery and development, two protagonists emerge as the cornerstones of modern medicine: biologics and small molecules. Biologics: Biologics are large, complex molecules, often proteins, that are produced using living cells.

Development 97

Development Drugs Immune Response Manufacturing 97

pharmaphorum

JANUARY 12, 2021

This is particularly important in developing countries, where access to cold-chain is limited,” said Channon. For instance, oral vaccines could allow repeat dosing without a treatment-limiting anti-vector response – where the body generates an immune response against the harmless, non-replicating viruses used to deliver the COVID-19 antigens.

Licensing 119

Licensing Licensing Vaccine Vaccination 119

Pfizer

JULY 26, 2022

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. deliesschef. Tue, 07/26/2022 - 17:41.

Vaccine 111

Vaccine Vaccination Protein Immune Response 111

Pharmaceutical Technology

FEBRUARY 15, 2023

The structural proteins include the capsid, pre-membrane/membrane proteins and envelope (E) proteins. The non-structural proteins NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 are involved in viral RNA replication and dampening of the host innate immune response.

Vaccine 130

Vaccine Vaccination Protein Immune Response 130

Pharmaceutical Technology

MAY 17, 2023

It has been designed for controlling the complement factor C5a, which is a protein that plays an important and harmful role in the immune response of the body. The treatment is an investigational first-in-class monoclonal anti-human complement factor C5a antibody.

Manufacturing 130

Manufacturing Immune Response Protein Antibody 130

XTalks

OCTOBER 12, 2021

The experimental arthritis vaccine was developed by researchers at the University of Toledo (UToledo) and is a major breakthrough for rheumatoid arthritis and other autoimmune diseases as well. The vaccine was tested in rats and showed strong, immediate and long-lasting immune responses to confer protection against the disease.

Vaccine 105

Vaccine Vaccination Research Immune Response 105

pharmaphorum

FEBRUARY 22, 2021

Sanofi and GlaxoSmithKline are restarting clinical development of their COVID-19 vaccine, which was delayed after hitting a snag late last year. In December interim phase 1/2 trial results showed the vaccine produced a lower immune response in older adults.

Vaccine 89

Vaccine Vaccination Recombinant DNA Technology Trials 89

pharmaphorum

FEBRUARY 9, 2022

However, the industry is constantly looking to discover the next frontier in treatment development and technology to provide more effective, safer treatments to patients. One area that is gathering increasing levels of interest is the development of cancer vaccines. A broad front. Prior success.

Vaccine 134

Vaccine Vaccination Clinical Trials Clinical Trials 134

XTalks

AUGUST 26, 2020

The anti-inflammatory macrophages help in preventing an immune response from becoming dangerous, as seen with patients with autoimmune disease. This helps to ensure that inflammation naturally subsides after the initial immune response and promotes tissue repair.

Bacteria 105

Bacteria Immune Response Protein Medicine 105

The Pharma Data

FEBRUARY 22, 2021

Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate. New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults. In parallel, development work on new SARS-CoV-2 variants underway.

Protein 52

Protein Vaccine Vaccination Immune Response 52

The Pharma Data

MAY 16, 2021

Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups. High immune response after a single dose in patients with prior infection shows strong booster potential. For media and investors only. Issued: London UK. About the Phase 2 study.

Immune Response 52

Immune Response Vaccine Vaccination Trials 52

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. Graves explained the gene therapy platform delivers plasmid DNA that enables a patient’s own cells to produce therapeutic proteins that work to clear harmful virus particles from healthy tissues.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccine Vaccination 75

pharmaphorum

AUGUST 11, 2021

It is the first COVID-19 vaccine developed in South Korea to reach the pivotal trial stage, and from the earliest stages of its development has been earmarked as a possible candidate for rollout at scale across developing countries via the COVAX programme.

Vaccine 98

Vaccine Vaccination Immune Response Protein 98

pharmaphorum

MARCH 23, 2021

US biotech Aura Biosciences has closed an oversubscribed financing, raising $80 million to help take its lead virus-like drug conjugate (VDC) for a cancer that affects the eye into late-stage development. The post Aura raises $80m to develop its virus-like cancer drugs appeared first on.

Development 71

Development Drugs Immune Response Life Science 71

pharmaphorum

JULY 20, 2021

The vaccine – now dubbed Vidprevtyn – is based on a recombinant protein antigen developed by Sanofi’s vaccines unit Sanofi Pasteur, and also includes an immune-boosting adjuvant developed by GSK that aims to boost its efficacy. 1.351) variant first identified in South Africa.

Vaccine 98

Vaccine Vaccination Protein Immune Response 98

The Pharma Data

DECEMBER 16, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of New Zealand for the purchase of 10.7 NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.

Protein 52

Protein Vaccine Vaccination Immune Response 52

The Pharma Data

AUGUST 15, 2021

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants. bioRxiv [Preprint]. 2021 Apr 8:2021.04.08.438884.

Protein 52

Protein Vaccine Vaccination Antibody 52

Pharmaceutical Technology

FEBRUARY 15, 2023

The key component in all vaccines is one or more active ingredients made from viruses or bacteria, also called antigens, which generates an immune response. The active component of the Pfizer-BioNTech vaccine tozinameran, contains the genetic code for the coronavirus spike protein, inside a lipid (fat) capsule.

Vaccine 130

Vaccine Vaccination Containment Immune Response 130

pharmaphorum

APRIL 8, 2022

The Dublin-based pharma is paying $15 million upfront for global rights to Werewolf’s WTX-613, a prodrug of the cytokine interferon alfa-2b, which is still back n preclinical development and due to start its first clinical trials next year. Once within the tumour, it stimulates receptors on immune cells to mount an attack on the cancer.

Drugs 105

Drugs Immune Response Licensing Licensing 105

pharmaphorum

OCTOBER 17, 2022

And yet, while researchers have proven that reprogramming or boosting a patient’s own immune system to attack cancerous cells can bring a long-lasting effect, it is not one that benefits all patients. Some tumour types show primary resistance, while others develop adaptive or secondary resistance.

Immune Response 115

Immune Response Development Research Protein 115

Pharmaceutical Technology

AUGUST 24, 2022

Patients provide blood samples for clinical trial sponsors to develop and deliver these emerging immunotherapies. Each sample they give is precious, as they all provide a wealth of biological data that contributes to therapy development. The data are used for decision-making during drug development (purpose).

Clinical Trials 130

Clinical Trials Clinical Trials Trials Development 130

XTalks

DECEMBER 12, 2023

Plasma medicine is a critical and specialized field within healthcare, centering on the use of human plasma for the development and administration of life-saving treatments. Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111

pharmaphorum

AUGUST 16, 2020

The European Commission has placed its first advance order for a coronavirus vaccine, snapping up 300 million doses of AstraZeneca’s ChAdOx1 candidate developed by the University of Oxford, with an option on another 100 million. The EU says its advance purchase order will finance part of the upfront costs of developing the vaccine.

Vaccine 111

Vaccine Vaccination Immune Response Trials 111

XTalks

JUNE 15, 2022

The Novavax candidate NVX-CoV2373 is a protein-based vaccine developed using recombinant nanoparticle technology. protein that triggers the immune system to generate antibodies against the virus. Adjuvants can help boost the effectiveness of a vaccine and elicit a stronger immune response.

Vaccine 59

Vaccine Vaccination Immune Response Protein 59

pharmaphorum

SEPTEMBER 1, 2020

AstraZeneca has expanded development of COVID-19 vaccine AZD1222 into the US, beginning a phase 3 clinical trial across all adult age groups. The UK pharma said that the trial will recruit up to 30,000 adults aged 18 years or over to assess the safety, efficacy and immune response.

Vaccine 69

Vaccine Vaccination Trials Immune Response 69

The Pharma Data

NOVEMBER 30, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. About NVX-CoV2373 NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease.

Clinical Development 52

Clinical Development Vaccine Vaccination Development 52

XTalks

DECEMBER 14, 2021

Moderna revealed the first interim results from a small, Phase I study of its mRNA-based influenza vaccine, which showed that the vaccine had no significant safety concerns and elicited immune responses against four strains of the influenza virus. Moderna isn’t the only one with mRNA-based influenza vaccines in development.

Vaccine 98

Vaccine Vaccination Immune Response Antibody 98